baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

TG Therapeutics/ US88322Q1085 /

2024-06-14 9:59:59 PM	Chg. -0.20	Volume	Bid-	Ask-	High	Low
16.56USD	-1.19%	89,643 Turnover: 1.48 mill.	-Bid Size: -	-Ask Size: -	16.95	16.25

GlobeNewswire 06-11 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...

GlobeNewswire 06-07 TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 06-03 TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire 05-31 TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024...

GlobeNewswire 05-28 TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple ...

GlobeNewswire 05-01 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire 04-30 TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

GlobeNewswire 04-18 TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple ...

GlobeNewswire 04-18 TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the P...

GlobeNewswire 04-15 TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis...

GlobeNewswire 03-08 TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Scle...

GlobeNewswire 03-01 TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Co...

GlobeNewswire 02-28 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Resu...

GlobeNewswire 02-27 TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

GlobeNewswire 02-26 TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

GlobeNewswire 02-23 TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Bu...

GlobeNewswire 02-20 TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Scle...

GlobeNewswire 01-09 TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development an...

GlobeNewswire 01-05 TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-11-27 TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

GlobeNewswire 2023-11-03 TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (IN...

GlobeNewswire 2023-11-01 TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-10-30 TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

GlobeNewswire 2023-10-12 TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatm...

GlobeNewswire 2023-10-11 TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatm...

TG Therapeutics/ US88322Q1085 /

If you wish to receive reply to your feedback, please provide your email address.